Patents for A61P 35 - Antineoplastic agents (221,099)
04/2006
04/13/2006WO2006038880A1 New composition and method
04/13/2006WO2006038865A1 Nucleotide derivatives for the treatment of type 2 diabetes and other disorders
04/13/2006WO2006038738A1 Receptor function regulating agent
04/13/2006WO2006038680A1 2-arylcarboxamide-nitrogeneous heterocycle compound
04/13/2006WO2006038608A1 Oligo double-stranded rna and medicinal composition
04/13/2006WO2006038606A1 Biaryl derivative
04/13/2006WO2006038527A1 Antitumor immunostimulant containing extract from pleurotus cornucopiae as active ingredient
04/13/2006WO2006038526A1 Acid addition salt of irinotecan
04/13/2006WO2006038111A1 Benzoimidazole derivatives useful as antiproliferative agents
04/13/2006WO2006037875A1 Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors
04/13/2006WO2006037848A1 Method and preparation for binding aldehydes in saliva
04/13/2006WO2006037761A1 New histone deacetylases inhibitors
04/13/2006WO2006037604A1 Novel antibodies directed to the mammalian eag1 ion channel protein
04/13/2006WO2006024770A3 Phosphole derivatives complexed with metals, and pharmaceutical uses thereof
04/13/2006WO2006019327A3 Deuterium depleted water (ddw) using as adjuvant in cancer therapy for cytostatics toxicity reduction
04/13/2006WO2006018185A3 Dihydropteridinones for the treatment of cancer diseases
04/13/2006WO2006005602A3 Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
04/13/2006WO2005116032A3 Reverse-turn mimetics and method relating thereto
04/13/2006WO2005056058A3 Radiosensitizer conjugate to improve the efficacy of radiolabeled drugs
04/13/2006US20060079707 Cyclization by reacting 4-(2-CHLORO-4-TRIFLUOROMETHYL-PHENYL)-4-CYANO-BUT-3-ENOIC ACID METHYL ESTER in the presence of a palladium catalyst and a base; chemical intermediates for preparing 10-AZA-TRICYCLO[6.3.1.02,7] drugs; bind nicotinic acetylcholine receptor, modulate cholinergic function
04/13/2006US20060079692 Synthesis of indole thiazole compounds as ligands for the Ah receptor
04/13/2006US20060079688 Process for producing acid adduct salt of polyacidic base compound
04/13/2006US20060079677 Novel tricyclic azepine derivatives, method for production thereof and pharmaceutical compositions comprising the same
04/13/2006US20060079670 98 human secreted proteins
04/13/2006US20060079577 Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
04/13/2006US20060079575 Anticancer agent for drug resistant cancer
04/13/2006US20060079572 Novel bioactive substance
04/13/2006US20060079563 Cyclic protein tyrosine kinase inhibitors
04/13/2006US20060079551 Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors
04/13/2006US20060079548 Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
04/13/2006US20060079534 Cell division inhibitor and a production method thereof
04/13/2006US20060079530 Farnesyl transferase inhibitors
04/13/2006US20060079528 Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
04/13/2006US20060079527 Compounds such as 1-[4-(3,4-difluoro-phenyl) -piperazin-1 -yl]-3-{methyl-[2-(9H-xanthen-9-yl)-ethyl]-amino}-propan-1 -one in free base or acid addition salt form, for therapy of depression, anxiety and bipolar disorders
04/13/2006US20060079503 Thiazolidinones and the use therof as polo-like kinase inhibitors
04/13/2006US20060079493 Such as rheumatoid arthritis or cancer, with HSP90 inhibitor such as 17-allylaminogeldanamycin (17-AAG), geldanamycin, herbimycin A, and macbecin; pharmacogenetics
04/13/2006US20060079480 Novel antifolate combination therapies
04/13/2006US20060079470 Combined dna vaccine and biological modifiers for cancer therapy
04/13/2006US20060079458 Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
04/13/2006US20060079451 Heparin-binding proteins modified with sugar chains, method of producing the same and pharmaceutical compositions containing same
04/13/2006US20060078980 Production of polyketides and other natural products
04/13/2006US20060078975 Crystal structure of enzyme and uses thereof
04/13/2006US20060078971 Isoflavone-beta-D-glucan produced by Agaricus blazei in the submerged liquid culture and method of producing same
04/13/2006US20060078956 Methods to identify compounds that modulate rage
04/13/2006US20060078940 21132, a human G-protein coupled receptor family member and uses therefor
04/13/2006US20060078918 Detecting the activity of orphan G Protein Receptor 86 by incubating a sample comprising GPR86 and adenosine diphosphate (ADP) under binding conditions for both and detecting a second messanger; screening for a modulator
04/13/2006US20060078879 Polymorphisms in the human gene for tpmt and their use in diagnostic and therapeutic applications
04/13/2006US20060078878 Cell containing nucleic acid molecule comprising polynucleotide sequence encoding engineered zinc finger protein operably linked to promoter, contacting target site in endogenous cellular gene with protein to inhibit transcription
04/13/2006US20060078607 Liposome formulation of 6,9-bis[(2-aminoethyl)-amino]benzo[g]isoquinoline-5, 10-dione dimaleate
04/13/2006US20060078575 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics
04/13/2006US20060078563 Using heat shock proteins to increase immune response
04/13/2006US20060078547 Lactobacillus salivarius strain, AH102, AH103, AH105, AH109 or AH110 or mutants or variants are useful in the prophylaxis and/or treatment undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome
04/13/2006US20060078539 Remedies for tumor in hematopoietic organs
04/13/2006DE10320633B4 Verfahren zur Identifizierung einer möglichen Modifikation von mindestens einem biologischen Parameter unter Verwendung von lebenden Zellen, die einem Reiz ausgesetzt wurden, und lebenden Zellen, die nicht diesem Reiz ausgesetzt wurden A method of identifying a possible modification of at least one biological parameter using living cells that were exposed to a stimulus, and living cells that were not exposed to this stimulus
04/13/2006CA2583326A1 Receptor function regulating agent
04/13/2006CA2582963A1 T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
04/13/2006CA2582949A1 Liposomes with improved drug retention for treatment of cancer
04/13/2006CA2582908A1 Macrocyclic sh2 domain binding inhibitors
04/13/2006CA2582683A1 Novel antibodies directed to the mammalian eag1 ion channel protein
04/13/2006CA2582668A1 Nanoparticles comprising antigens and adjuvants, and immunogenic structures
04/13/2006CA2582327A1 2-arylcarboxamide-nitrogeneous heterocycle compound
04/13/2006CA2582289A1 Inhibition of tumour cell migration
04/13/2006CA2580831A1 Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors
04/13/2006CA2562151A1 Oligonucleotides comprising a c5-modified pyrimidine
04/12/2006EP1645624A1 Nerve cells obtained by electrical pulse treatment es cell
04/12/2006EP1645556A1 Arylpiperazine-benzoylamide derivatives useful as pharmaceutical agents
04/12/2006EP1645288A1 New nuclear transcription factors regulators
04/12/2006EP1645284A1 Use of ligands of the antigen CDw52 for the treatment of diseases that are related to degenerated macrophages
04/12/2006EP1645280A1 Use of angelicae sinensis extracts in the treatment of cancers and method for inhibiting an activity of cancer cells
04/12/2006EP1645198A1 Process for producing liquid formulation containing raw yeast and liquid formulation
04/12/2006EP1644729A2 Anti-cd74 immunoconjugates and methods
04/12/2006EP1644403A2 Cytotoxic depsipeptides
04/12/2006EP1644385A1 Silicon compounds and their use
04/12/2006EP1644380A2 Biologically active neopeltolide compounds
04/12/2006EP1644377A1 Triazolotriazine compounds and uses thereof
04/12/2006EP1644376A1 PYRROLO 3,4-c PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS
04/12/2006EP1644361A1 Chinazoline derivatives as aurora kinase inhibitors
04/12/2006EP1644360A1 3-substituted indoles and derivatives thereof as therapeutic agents
04/12/2006EP1644359A2 Metabolites of tricyclic amides useful for inhibition of g-protein function and methods of treatment of proliferative diseases
04/12/2006EP1644350A1 Sulfamate benzothiophene derivatives as steroid sulfatase inhibitors
04/12/2006EP1644338A1 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
04/12/2006EP1644323A2 Histone deacetylase inhibitors and methods of use thereof
04/12/2006EP1644050A1 Bifunctional tridentate pyrazolyl containing ligands for re, tc and mn tricarbonyl complexes
04/12/2006EP1644049A2 Method and device for radiotherapy
04/12/2006EP1644038A2 Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
04/12/2006EP1644032A1 Inhibitors of cell migration
04/12/2006EP1644031A1 Inhibitors of the leukocyte prommp-9/beta(2) integrin complex
04/12/2006EP1644003A1 Triazolo ´1,5-a!pyrimidines and their use in medicine
04/12/2006EP1644001A2 Pancratistatin cyclic phosphate prodrugs an phenpanstatin cyclic phosphate prodrugs
04/12/2006EP1643991A1 Benzimidazole carboxamides as raf kinase inhibitors
04/12/2006EP1643989A1 Cis-imidazolines as mdm2 inhibitors
04/12/2006EP1643984A2 Use of parthenolide derivatives as antileukemic and cytotoxic agents
04/12/2006EP1643971A2 Liposomal formulations comprising a combination of two or more active agents
04/12/2006EP1643836A1 Arylmethyl triazolo and imidazopyrazines as c-met inhibitors
04/12/2006EP1560826B1 Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same
04/12/2006EP1556380B1 Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, preparation thereof and application of same in therapeutics
04/12/2006EP1423436B1 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
04/12/2006EP1358183B1 Cysteine protease inhibitors
04/12/2006EP1345920B1 Novel sulfamides and their use as endothelin receptor antagonists
04/12/2006EP1331940B1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2